secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001104659-24-100239
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Brainstorm Cell shareholders OK 150M authorized share increase, reverse split, equity plan boost
--------------------------------------------------------------------------------

- Stockholders approved increasing authorized common shares from 100M to 250M.
- Board authorized to effect reverse stock split of 1:5 to 1:15 at any time before Sept 16, 2025.
- Equity plan share pool increased by 8M shares to 13.6M; each plan extended to 2034.
- All seven director nominees elected; Brightman Almagor Zohar & Co. ratified as auditor.
- Advisory vote on executive compensation approved with a 3-year frequency for future votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/0001104659-24-100239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-100239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer